ClinVar Miner

Submissions for variant NM_004333.6(BRAF):c.1411G>A (p.Val471Ile)

dbSNP: rs121913376
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000033309 SCV000057214 likely pathogenic not provided 2012-08-30 criteria provided, single submitter clinical testing The V471I missense change has not been published as a germline mutation, nor has it been reported as a benign polymorphism to our knowledge. The NHLBI ESP Exome Variant Server reports that V471I was not observed in approximately 5,000 samples from individuals of European and African American backgrounds, indicating it is not a common benign variant in these populations. The V471I amino acid substitution is conservative as both Valine and Isoleucine are neutral and non-polar residues. However, the V471 position is highly conserved across species and in related proteins. A different mutation (V471F) at this same position and many other missense mutations of nearby codons (S467A, F468S, G469E, L485F, L485S) have been published in association with cardio-facio-cutaneous syndrome (CFC) (Abe et al., 2012; Rodriguez-Viciana et al., 2006; Niihori et al., 2006; Rodriguez-Viciana et al., 2008; Aoki et al., 2008). Therefore, V471I is a strong candidate for a disease-causing mutation, although the possibility that it is a benign polymorphism cannot be excluded. The variant is found in NOONAN panel(s).

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.